indexado en
  • Abrir puerta J
  • Claves Académicas
  • InvestigaciónBiblia
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Centro Internacional de Agricultura y Biociencias (CABI)
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • CABI texto completo
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • Google Académico
Comparte esta página
Folleto de diario
Flyer image

Abstracto

Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field

Adriano C. Coelho

Miltefosine is the first effective oral drug used in the chemotherapy of leishmaniasis. The drug is more effective than pentavalent antimonials that are still considered as the drug of choice for treatment of leishmaniasis in several endemic regions. Efficacy rates of miltefosine against visceral leishmaniasis are up to 95%, while against cutaneous leishmaniasis the rates vary between 53% and 91% depending on the species of the parasite and the endemic region. Recent reports have described an increased number of relapses in miltefosine-treated patients. This review describes the main findings associated with miltefosine susceptibility and resistance in Leishmania: two important factors involved in efficacy and failure in leishmaniasis treatment using this drug.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado